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Resistance of brain tumors to therapy and their eventual recurrence is attributed to stem-like cells. In this
issue of Cell Stem Cell, a high-throughput kinome-wide screen (Wurdak et al., 2010) has identified TRRAP,
a kinase-related protein, as being required for stem cell character in gliomas.The prognosis for treatment of glioblas-
tomas remains dismal (a little more than
1 year), and research toward a better
understanding of the biology of thera-
peutic resistance for this disease is
actively ongoing. One proposed reason
for the poor response to treatment is the
existence of a small subpopulation of
resistant cells within these tumors that
survive treatment and repopulate the
tumor. These resistant cells have proper-
ties similar to stem cells, and isolation
of this subpopulation, referred to as brain
tumor-initiating cells (BTICs) or brain
tumor stem-like cells, was first achieved
by utilizing the hematopoietic stem cell
marker CD133 (Singh et al., 2004). In their
study, the authors showed that this cell
population from human glioblastoma
samples could regenerate tumors with
phenotypes comparable to those from the
patient more efficiently than their CD133-
negative counterparts. These stem-like
cells contribute to the glioma’s resistance
to therapy (Bao et al., 2006). The data
suggest that the stem cell-like properties
of BTICs are important factors mediating
tumor resistance and recurrence and
that novel strategies that specifically tar-
get this population may be essential for
improved therapeutic outcomes. Several
signaling pathways including Notch, Shh,
and PI3K are known to regulate the
activity of normal neural stem cells (Stiles
and Rowitch, 2008), implying that kinasesregulate this phenotype. These signaling
pathways similarly regulate the activity of
BTICs and may represent one approach
to directly target BTICs. The bone mor-
phogenic proteins (BMPs) induce differ-
entiation of neural stem cells into mature
astrocytes and BMP4 induces differentia-
tion of BTICs in gliomas (Piccirillo et al.,
2006). By enforcing the differentiation of
BTICs in this manner, one might predict
that tumor recurrence would be less likely,
because the stem cell properties of
the tumor cells should be lost in the
more mature progeny. This approach
was successfully employed in the treat-
ment of promyelocytic leukemia (Wang
et al., 1998).
In this issue of Cell Stem Cell, a manu-
script from the Schultz laboratory (Wurdak
et al., 2010) provides further insight into
this phenomenon and important experi-
mental evidence to justify targeting of
BTICs with differentiating factors. The
authors used a phenotypic high-through-
put shRNA library screen targeting the
kinome to identify genes involved in the
maintenance of ‘‘stemness’’ in gliomas,
with BMP4 treatment as a positive control.
The authors identified many expected
kinases such as IGFR, as well as MAP
and SRC family kinases. In addition, they
identified TRRAP, an adaptor protein
with homology to the PIKK kinases
but lacking intrinsic kinase activity, as
playing a role in the differentiation phe-notype in glioblastoma stem-like cells.
TRRAP is thought to regulate many
biologic functions including chromatin
remodeling, embryonic development,
oncogenic transformation through c-Myc
and E2F, as well as cell cycle progression.
The authors report that knockdown of
TRRAP in BTICs (grown as a monolayer
on laminin) resulted in many phenotypic
changes consistent with loss of stem
cell characteristics (Figure 1) including
decreased neurosphere formation in
culture, decreased tumor formation upon
transplantation into recipient mice, in-
creased sensitivity to temozolomide and
radiation therapy, and alteration of mar-
kers associated with differentiation such
as loss of Nestin and Sox2 with gain of
GFAP and TuJ1. The data imply that
TRRAP loss depletes the stem-like pool of
BTICs in vitro and mirrors the effects first
reported for BMP4 (Piccirillo et al., 2006).
Given the presented data on loss of func-
tion, one might expect overexpression of
TRRAP to promote stem cell character
and tumorigenic potential in these BTICs;
in fact, TRRAP gene expression was
elevated in the gliomas analyzed in this
study.
The effects on proliferation and differ-
entiation induced by TRRAP knockdown
appeared to be mediated in part by
suppression of transcriptional activity for
the mitotic cyclin A2 with associated
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Figure 1. The Effects of TRRAP Knockdown on Glioblastoma Brain Tumor-Initiating Cells
Primary glioma samples are composed of a heterogeneous population of tumor cells, a small subset of which are the BTICs. In vitro culture of the primary tumor
enriches the population of BTICs, which when targeted with TRRAP shRNAs differentiate to an astrocytic lineage. TRRAP knockdown suppresses cyclin A2 gene
expression, inhibits cell cycle progression, and elevates BMP/Smad signaling in BTICs, which severely weakens their tumorigenicity when engrafted in mice.
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signaling. The authors suggest that cyclin
A2 may play a pivotal role in promoting
the BTIC stem-like phenotype. There are
data to support this possibility, because
cyclin A2 overexpression was previously
shown to confer anchorage-indepen-
dent growth in cells (Barrett et al., 1995).
Furthermore, connections may exist
between cyclin A2 and differentiation of
BTICs, as shown by the fact that the loss
of cyclin A2 activity has been linked to
stem cell differentiation (Chen et al.,
2009). In addition, loss of cyclin A2 activity
was recently shown to preferentially
decrease the proliferation of hematopoi-
etic and embryonic stem cells and to
suppress their capacity to generate
colony-forming units in comparison to
their more differentiated counterparts
(Kalaszczynska et al., 2009). In the con-
text of these previous reports combined
with the Wurdak et al. (2010) study, overall
the data suggest that the decreased
proliferation of BTICs observed after the
loss of cyclin A2 may be connected to
their differentiation status, potentially
suggesting a role for cyclin A2 in differen-
tiation of BTICs. Control of symmetrical
and asymmetrical cell division is certainly
part of stem cell character; however, thisfinding brings up the larger issue of
how to deconvolute proliferation from
stemness in experimental paradigms
such as transplantation models or growth
of neurospheres in cell culture.
Another important question raised by
this work is whether the function of TRRAP
or cyclin A2 is a central feature of stem-like
cells in all glioma subtypes. Gliomas are
classified into several subtypes based on
their gene expression and signal trans-
duction profiles (Brennan et al., 2009). In
this context, if genes regulating BTIC
character were analyzed in gliomas
distinguished by subtype, would there
be specific genes that would show up in
one subtype or another? For example,
would BTICs isolated from gliomas with
EGFR amplification respond to TRRAP or
cyclin A2 knockdown in tumors in a
similar way as do the PDGFR-amplified
subtypes? Could it be that within any given
tumor there are several different stem-like
cell types that are driven by different
genes? The work by Wurdak et al. (2010)
certainly strengthens the notion thatBTICs
could be targeted specifically through
manipulation of pathways that affect their
differentiation and provides exciting new
insight into the regulation of brain tumor
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